Dimethylformamide

Dimethylformamide

SCHEMBL175328

CCc1ccc(C[Zn]Br)cc1.CN(C)C=O

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.37
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.35
CA2 P00918 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33
TP53 P04637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
MGLL Q99685 2/20 0.32
PLK1 P53350 1/20 0.32
CYP2A6 P11509 1/20 0.32
LPL P06858 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
EGFR P00533 1/20 0.32
IGF1R P08069 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158407 0.83 TP53 (0.46) ALDH1A1LMNASMN1; SMN2TSHRCA2
Dimethylformamide SCHEMBL175329 0.76 HPGD (0.39) HPGDALDH1A1LMNAMAPTSMN1; SMN2
Ethylbenzene SCHEMBL14965882 0.75 TP53 (0.64) ALDH1A1LMNAMAPTSMN1; SMN2TSHR
Dimethylformamide SCHEMBL175327 0.74 HPGD (0.38) HPGDALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL8361530 0.69 HPGD (0.40) HPGDALDH1A1LMNAMAPTSMN1; SMN2
Trimethylammonium SCHEMBL27719445 0.68 TP53 (0.56) HPGDALDH1A1LMNASMN1; SMN2TSHR
SCHEMBL4634848 0.67 ALDH1A1 (0.40) HPGDALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL6688169 0.67 ALDH1A1 (0.40) HPGDALDH1A1LMNAMAPTSMN1; SMN2
Propionaldehyde SCHEMBL27616242 0.67 ALDH1A1 (0.53) HPGDALDH1A1LMNAMAPTSMN1; SMN2
Formamide SCHEMBL27349688 0.67 TAAR1 (0.52) HPGDALDH1A1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 HPGD 612/4885ALDH1A1 873/4885LMNA 1887/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 HPGD 612/4885ALDH1A1 873/4885LMNA 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.